Stay updated with breaking news from Ongoing Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Montrouge, France, November 9, 2023DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPE...
Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses and 31% disease control rate across all dose levels in a range of solid tumor types, including...
– ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly...
Achieved significant enrollment milestones in three ongoing Phase 2 clinical trialsBroadened patent protection for proprietary -endoxifenStrengthened management team with appointment of Greg Weaver as... -Today at 08:32 am- MarketScreener
BUSINESS SECTION Overview Company Overview We are a clinical-stage biopharmaceutical company focused on developing...